[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Stock.Logging [@stock_logging](/creator/twitter/stock_logging) on x XXX followers Created: 2025-07-24 14:11:33 UTC $KRYS Strong study results for Krystal Biotech and its subsidiary Jeune Aesthetics In a randomized, double-blind and placebo-controlled Phase X study, pipeline candidate KB301 showed significant improvements in severe wrinkles in the décolleté area over 1–3 months – as assessed by both investigators (left column) and patients themselves (right column). Important: There is currently no FDA-approved injectable treatment for the décolleté area. Investing in $KRYS therefore not only gives exposure to the market leader in the treatment of dystrophic epidermolysis bullosa (DEB), a rare skin disease, but also offers a potential call option on Jeune Aesthetics, which targets the multi-billion-dollar aesthetic treatment market. According to the CEO of $KRYS, Jeune is expected to be spun off someday, which could unlock additional value for shareholders. Also worth mentioning is Jeune’s recently appointed CEO, Marc Forth, who played a key role in the commercialization of BOTOX in a previous role and is therefore a true industry veteran. While Krystal isn’t a super high-conviction position for me (recent quarterly numbers were a bit disappointing), it’s a solid addition to my biotech basket. Current valuation (analyst consensus): ➢ 2025 fwd P/E: XXXX ➢ 2026 fwd P/E: XXXX ➢ 2027 fwd P/E: XXXX  XXX engagements  **Related Topics** [$krys](/topic/$krys) [Post Link](https://x.com/stock_logging/status/1948385568758370719)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Stock.Logging @stock_logging on x XXX followers
Created: 2025-07-24 14:11:33 UTC
$KRYS Strong study results for Krystal Biotech and its subsidiary Jeune Aesthetics
In a randomized, double-blind and placebo-controlled Phase X study, pipeline candidate KB301 showed significant improvements in severe wrinkles in the décolleté area over 1–3 months – as assessed by both investigators (left column) and patients themselves (right column).
Important: There is currently no FDA-approved injectable treatment for the décolleté area. Investing in $KRYS therefore not only gives exposure to the market leader in the treatment of dystrophic epidermolysis bullosa (DEB), a rare skin disease, but also offers a potential call option on Jeune Aesthetics, which targets the multi-billion-dollar aesthetic treatment market.
According to the CEO of $KRYS, Jeune is expected to be spun off someday, which could unlock additional value for shareholders. Also worth mentioning is Jeune’s recently appointed CEO, Marc Forth, who played a key role in the commercialization of BOTOX in a previous role and is therefore a true industry veteran.
While Krystal isn’t a super high-conviction position for me (recent quarterly numbers were a bit disappointing), it’s a solid addition to my biotech basket.
Current valuation (analyst consensus):
➢ 2025 fwd P/E: XXXX ➢ 2026 fwd P/E: XXXX ➢ 2027 fwd P/E: XXXX
XXX engagements
Related Topics $krys